Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
35
Recruiting, any sponsor type, condition "hidradenitis suppurativa"
By trial status
The same filters, counted in each status. Pick one to switch.
35 trials
Showing 1 to 25, recently updated first.
- A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial)Pivotal-lookingRecruiting
Spyre Therapeutics, Inc.Industry
NCT07766005 · 150 participants (planned) · Start Oct 6, 2026 · Primary completion Oct 2027
Drug: SPY072; Placebo and 1 more · For: Hidradenitis Suppurativa (HS)
Sites: Birmingham, Alabama; Rogers, Arkansas; Irvine, California · 34 sites in all
- Rollover Study for Participants Previously Enrolled in Clinical Trials of PovorcitinibPivotal-lookingRecruiting
Incyte CorporationIncyte (INCY)
NCT06855498 · 600 participants (planned) · Start Feb 28, 2025 · Primary completion Feb 28, 2028
Drug: povorcitinib · For: Hidradenitis Suppurativa (HS)
Sites: Birmingham, Alabama; Montgomery, Alabama; Phoenix, Arizona · 305 sites in all
Incyte CorporationIncyte (INCY)
NCT07213973 · 40 participants (planned) · Start Feb 2, 2026 · Primary completion Mar 25, 2028
Drug: Povorcitinib · For: Hidradenitis Suppurativa (HS)
Sites: Birmingham, Alabama; Phoenix, Arizona; Farmington, Connecticut · 28 sites in all
- A Study to Explore the Tissue Level Effects of Remibrutinib in Adults With Moderate to Severe HSRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07855276 · 30 participants (planned) · Start Oct 29, 2026 · Primary completion Nov 29, 2027
Drug: LOU064; Placebo · For: Hidradenitis Suppurativa
Sites: San Diego, California; Mayfield Heights, Ohio
- Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or ObesityPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07830329 · 300 participants (planned) · Start Oct 29, 2026 · Primary completion Nov 24, 2028
Drug: Olatorepatide; Placebo · For: Hidradenitis Suppurativa
Sites: The Bronx, New York
- A Study to Investigate Efficacy and Safety of Duvakitug in Adult Participants With Moderate to Severe Hidradenitis SuppurativaPivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07812116 · 156 participants (planned) · Start Oct 19, 2026 · Primary completion Jun 16, 2028
Drug: Duvakitug; Placebo · For: Hidradenitis
Sites: Birmingham, Alabama; Miami, Florida; Peterborough, Canada · 4 sites in all
- An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HSPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07665437 · 710 participants (planned) · Start Jul 10, 2026 · Primary completion Oct 15, 2031
Drug: Remibrutinib · For: Hidradenitis Suppurativa
Sites: Birmingham, Alabama; Fort Smith, Arkansas; North Little Rock, Arkansas · 61 sites in all
- ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis SuppurativaPivotal-lookingRecruiting
Oruka Therapeutics, Inc.Industry
NCT07783542 · 200 participants (planned) · Start Aug 21, 2026 · Primary completion Oct 2028
Drug: ORKA-002 · For: Hidradenitis Suppurativa (HS)
Sites: Birmingham, Alabama; Fountain Valley, California; Los Angeles, California · 25 sites in all
- SAR447971 First-in-human StudyPivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07629336 · 122 participants (planned) · Start May 26, 2026 · Primary completion Apr 17, 2028
Drug: SAR447971; Placebo · For: Hidradenitis; Healthy Volunteers
Sites: Leiden, Netherlands
- A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis SuppurativaPivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07225569 · 144 participants (planned) · Start Dec 29, 2025 · Primary completion Sep 22, 2027
Drug: SAR445399; Placebo · For: Hidradenitis Suppurativa
Sites: Scottsdale, Arizona; North Hollywood, California; Boynton Beach, Florida · 86 sites in all
Corvus Pharmaceuticals, Inc.Industry
NCT07828860 · 25 participants (planned) · Start Sep 17, 2026 · Primary completion Dec 2027
Drug: Soquelitinib · For: Hidradenitis Suppurativa (HS)
Sites: West Lafayette, Indiana; Bowling Green, Kentucky; Owensboro, Kentucky · 11 sites in all
- Brivekimig for the Treatment of Moderate to Severe Hidradenitis SuppurativaPivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07170917 · 208 participants (planned) · Start Nov 6, 2025 · Primary completion Feb 9, 2027
Drug: Brivekimig; Placebo · For: Hidradenitis Suppurativa
Sites: Phoenix, Arizona; Scottsdale, Arizona; Northridge, California · 85 sites in all
Harrison DermatologyAcademic, hospital or other
NCT07689188 · 10 participants (planned) · Start Sep 10, 2026 · Primary completion Mar 10, 2028
Drug: Roflumilast 0.3% topical foam · For: Hidradenitis Suppurativa (HS)
Sites: Missouri City, Texas
Incyte CorporationIncyte (INCY)
NCT07049575 · 24 participants (planned) · Start Nov 3, 2025 · Primary completion Dec 9, 2026
Drug: Ruxolitinib Cream · For: Hidradenitis Suppurativa
Sites: Phoenix, Arizona; Fountain Valley, California; Northridge, California · 21 sites in all
NCT06888193 · 20 participants (planned) · Start Nov 5, 2025 · Primary completion Dec 31, 2027
Drug: Bimekizumab · For: Moderate to Severe Plaque Psoriasis; Psoriatic Arthritis; Axial Spondyloarthritis and 1 more
Sites: Santa Monica, California; South Miami, Florida; Boston, Massachusetts · 14 sites in all
University of Massachusetts, WorcesterAcademic, hospital or other
NCT05403710 · 20 participants (planned) · Start Jun 7, 2022 · Primary completion Apr 30, 2028
Drug: Botulinum toxin · For: Hidradenitis Suppurativa; Hyperhidrosis
Sites: Worcester, Massachusetts
Novartis PharmaceuticalsNovartis (NVS)
NCT07489573 · 36 participants (planned) · Start Jun 1, 2026 · Primary completion Sep 25, 2029
Drug: Secukinumab · For: Hidradenitis Suppurativa (HS)
Sites: Guangzhou, China; Shijiazhuang, China; Chengdu, China · 10 sites in all
University of MinnesotaAcademic, hospital or other
NCT06058520 · 16 participants (planned) · Start Dec 27, 2023 · Primary completion Dec 30, 2026
Drug: Fecal Microbiota - lyophilized; Placebo drug · For: Hidradenitis Suppurativa
Sites: Minneapolis, Minnesota
University of Alabama at BirminghamAcademic, hospital or other
NCT06326476 · 12 participants (planned) · Start May 9, 2025 · Primary completion Dec 31, 2027
Drug: Siplizumab · For: Hidradenitis Suppurativa
Sites: Birmingham, Alabama
University Hospital Schleswig-HolsteinAcademic, hospital or other
NCT05928169 · 1,000 participants (planned) · Start May 1, 2023 · Primary completion Apr 30, 2032
Drug: Topical and systemic drugs · For: Atopic Dermatitis; Psoriasis; Lichen Planus and 5 more
Sites: Kiel, Germany
Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.Industry
NCT06932003 · 12 participants (planned) · Start Jul 8, 2025 · Primary completion Oct 30, 2028
Drug: LT-002-158 Tablets · For: Hidradenitis Suppurativa (HS)
Sites: Beijing, China
Almirall, S.A.Industry
NCT07547813 · 50 participants (planned) · Start May 13, 2026 · Primary completion Feb 2027
Drug: LAD328 · For: Hidradenitis Suppurativa
Sites: Warsaw, Poland
- Exploration of Brain Functional Networks in Patients With Hidradenitis Suppurativa Using fMRIRecruiting
Second Xiangya Hospital of Central South UniversityAcademic, hospital or other
NCT07755670 · 80 participants (planned) · Start Jan 3, 2026 · Primary completion Jan 2027
Drug: Routine Biologic Therapy for Hidradenitis Suppurativa · For: Hidradenitis Suppurativa (HS)
Sites: Changsha, China
- A Study to Assess NAV-240 in Adult Participants With Hidradenitis SuppurativaPivotal-lookingRecruiting
Navigator Medicines, Inc.Industry
NCT07384975 · 150 participants (planned) · Start Jan 5, 2026 · Primary completion Sep 2027
Drug: NAV-240; Placebo to match NAV-240 · For: Hidradenitis Suppurativa (HS)
Sites: Phoenix, Arizona; Scottsdale, Arizona; Maitland, Florida · 41 sites in all
Beth Israel Deaconess Medical CenterAcademic, hospital or other
NCT07263230 · 20 participants (planned) · Start Sep 1, 2026 · Primary completion Aug 2028
Drug: Roflumilast 0.3% topical foam · For: Hidradenitis Suppurativa (HS)
Sites: Boston, Massachusetts
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.